Overall survival · adult cancer survivors from the following cancer sites: breast, colorectal, endometrial, ovarian and prostate cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to detection of recurrence · adult cancer survivors from the following cancer sites: breast, colorectal, endometrial, ovarian and prostate cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life (HRQoL) · adult cancer survivors from the following cancer sites: breast, colorectal, endometrial, ovarian and prostate cancer
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Anxiety · adult cancer survivors from the following cancer sites: breast, colorectal, endometrial, ovarian and prostate cancer
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Depression · adult cancer survivors from the following cancer sites: breast, colorectal, endometrial, ovarian and prostate cancer
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Costs · adult cancer survivors from the following cancer sites: breast, colorectal, endometrial, ovarian and prostate cancer
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Time to detection of recurrence · adult cancer survivors from the following cancer sites: breast, colon, colorectal, endometrial, ovarian, cervical, melanoma and oesophageal
1 finding from 1 review
no estimate extracted
1691 participants
Very low
Health‐related quality of life, (at 12 months' · adult cancer survivors from the following cancer sites: breast, colon, colorectal, endometrial, ovarian, cervical, melanoma and oesophageal
Non‐specialist‐led showed no clear difference in health‐related quality of life, (at 12 months' compared with specialist‐led follow‐up after primary cancer treatment (low certainty).
1 finding from 1 review
MD 1.06
605 participants
Low
Anxiety · adult cancer survivors from the following cancer sites: breast, colon, colorectal, endometrial, ovarian, cervical, melanoma and oesophageal
Non‐specialist‐led showed no clear difference in anxiety (at 12 months' compared with specialist‐led follow‐up after primary cancer treatment (moderate certainty).
1 finding from 1 review
MD 0.03
1266 participants
Moderate
Depressive symptoms · adult cancer survivors from the following cancer sites: breast, colon, colorectal, endometrial, ovarian, cervical, melanoma and oesophageal
Non‐specialist‐led showed no clear difference in depression (at 12 months) HADS‐Depression subscale (higher scores… compared with specialist‐led follow‐up after primary cancer treatment (high certainty).
1 finding from 1 review
MD 0.03
1266 participants
High
Costs · adult cancer survivors from the following cancer sites: breast, colon, colorectal, endometrial, ovarian, cervical, melanoma and oesophageal
1 finding from 1 review
no estimate extracted
1756 participants
Very low
All‐cause mortality up to 30 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major bleeding · patients undergoing non‐cardiac surgery/invasive procedures
It is very uncertain whether thromboelastography threshold changes major bleeding within 24 hours № of participants: 60 (1 RCT) compared with standard of care (laboratory parameters) (very low certainty).
1 finding from 1 review
RR 0.33 [0.01, 7.87]
Studies not reported
Very low
Number of transfusions per participant within 7 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of individuals requiring a transfusion within 7 days № of participants: 60 (1 RCT) · patients undergoing non‐cardiac surgery/invasive procedures
Thromboelastography threshold may leads to lower number of individuals requiring a transfusion within 7 days № of… compared with standard of care (laboratory parameters) (low certainty).
1 finding from 1 review
RR 0.18 [0.08, 0.39]
Studies not reported
Low
Serious adverse events measured by plasma transfusion‐related complications within 24 hours № of participants: 21 (1 RCT) · patients undergoing non‐cardiac surgery/invasive procedures
It is very uncertain whether thromboelastography threshold changes serious adverse events measured by plasma transfusion‐related… compared with standard of care (laboratory parameters) (very low certainty).
1 finding from 1 review
RR 0.33 [0.01, 7.87]
Studies not reported
Very low
Serious adverse events measured by surgery or procedure‐related complications within 30 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical failure · Children with extensive decay involving the dental pulp in primary teeth
Mineral trioxide aggregate (MTA) may leads to lower clinical failure compared with 3Mix (ciprofloxacin + metronidazole + minocycline) (low certainty).
1 finding from 1 review
Radiological failure · Children with extensive decay involving the dental pulp in primary teeth
Vitapex (calcium hydroxide/iodoform) showed no clear difference in radiological failure compared with 3Mix (ciprofloxacin + metronidazole + minocycline); GRADE not reported.
1 finding from 1 review